X-linked Ehlers-Danlos syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Mar 2026KRAZATI: New indication approved
FDAcompleted
Mar 2026ELREXFIO: New indication approved
FDAcompleted
Mar 2026ZYRTEC: New indication approved
FDAcompleted
Mar 2026XARELTO: New indication approved
FDAcompleted
Mar 2026XARELTO: New indication approved
FDAcompleted
Mar 2026XEOMIN: New indication approved
FDAcompleted
Mar 2026DHIVY: New indication approved
FDAcompleted
Mar 2026VYALEV: New indication approved
FDAcompleted
Mar 2026POLIVY: New indication approved
FDAcompleted
Feb 2026XEOMIN: New indication approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

5 programs

FINANCIAL LANDSCAPE SUMMARY

5

Total programs

5

Open now

1

Copay cards

Copay Assistance1

ZYRTEC

Kenvue Brands LLC

OpenContact for details

Patient Assistance Programs4

KANUMA

Alexion Pharmaceuticals, Inc.

OpenContact for detailsApply ↗

VIMIZIM

BioMarin Pharmaceutical Inc.

OpenContact for detailsApply ↗

POLIVY

Genentech, Inc.

OpenContact for detailsApply ↗

VYALEV

AbbVie Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for X-linked Ehlers-Danlos syndrome.
Search all trials →
Search clinical trials for X-linked Ehlers-Danlos syndrome

Recent News & Research

2 articles
BREAKINGFDA

FDA Approves POLIVY

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) received FDA approval.

Read ↗
BREAKINGFDA

FDA Approves PIROXICAM

PIROXICAM (PIROXICAM) received FDA approval.

Read ↗

Browse all X-linked Ehlers-Danlos syndrome news →

Specialist Network

Top 1 by expertise

View all X-linked Ehlers-Danlos syndrome specialists →

Quick Actions